Studies have found that HBOT can improve the common pathological angiogenesis of RA, and its mechanism is mainly through promoting the expression of PHD2, accelerating the degradation of HIF-1α, and inhibiting the production of angiogenic factor VEGFA (147). This evidence concerns the gene HIF1A and rheumatoid arthritis.